NASDAQ:MIST Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis $1.70 -0.01 (-0.58%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.70 0.00 (0.00%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Milestone Pharmaceuticals Stock (NASDAQ:MIST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MIST alerts:Sign Up Key Stats Today's Range$1.68▼$1.7250-Day Range$1.38▼$2.5652-Week Range$0.63▼$2.75Volume761,130 shsAverage Volume925,685 shsMarket Capitalization$144.48 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. Read More Milestone Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreMIST MarketRank™: Milestone Pharmaceuticals scored higher than 27% of companies evaluated by MarketBeat, and ranked 814th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingMilestone Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMilestone Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Milestone Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($0.62) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Milestone Pharmaceuticals is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Milestone Pharmaceuticals is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Milestone Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.13% of the float of Milestone Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMilestone Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Milestone Pharmaceuticals has recently increased by 10.35%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMilestone Pharmaceuticals does not currently pay a dividend.Dividend GrowthMilestone Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.13% of the float of Milestone Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMilestone Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Milestone Pharmaceuticals has recently increased by 10.35%, indicating that investor sentiment is decreasing significantly. News and Social Media1.0 / 5News Sentiment-0.24 News SentimentMilestone Pharmaceuticals has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Milestone Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for MIST on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Milestone Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders19.50% of the stock of Milestone Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Milestone Pharmaceuticals' insider trading history. Receive MIST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MIST Stock News HeadlinesMilestone® Pharmaceuticals to Present at Upcoming ConferencesAugust 19, 2025 | globenewswire.comMilestone Pharmaceuticals Advances CARDAMYST with FDA and Financial BoostAugust 13, 2025 | theglobeandmail.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. | Brownstone Research (Ad)Milestone Pharmaceuticals reports Q2 EPS (20c), consensus (18c)August 12, 2025 | msn.comMilestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateAugust 12, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Kestra Medical Technologies Ltd. (KMTS) and Milestone Pharmaceuticals (MIST)July 18, 2025 | theglobeandmail.comMilestone Pharmaceuticals Remains A Buying Opportunity Despite Recent DilutionJuly 18, 2025 | seekingalpha.comMilestone Pharmaceuticals Announces Public Offering for $48.7MJuly 16, 2025 | theglobeandmail.comSee More Headlines MIST Stock Analysis - Frequently Asked Questions How have MIST shares performed this year? Milestone Pharmaceuticals' stock was trading at $2.36 at the beginning of 2025. Since then, MIST stock has decreased by 28.0% and is now trading at $1.70. How were Milestone Pharmaceuticals' earnings last quarter? Milestone Pharmaceuticals Inc. (NASDAQ:MIST) released its earnings results on Tuesday, August, 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.02. When did Milestone Pharmaceuticals IPO? Milestone Pharmaceuticals (MIST) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Milestone Pharmaceuticals' major shareholders? Top institutional investors of Milestone Pharmaceuticals include Simplify Asset Management Inc. (1.85%), XTX Topco Ltd (0.30%), Valeo Financial Advisors LLC (0.24%) and Raymond James Financial Inc. (0.08%). Insiders that own company stock include Rtw Investments, Lp, Robert James Wills, David Bharucha and Debra K Liebert. View institutional ownership trends. How do I buy shares of Milestone Pharmaceuticals? Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Milestone Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Milestone Pharmaceuticals investors own include OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Tilray Brands (TLRY), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), Vaxart (VXRT) and Aquestive Therapeutics (AQST). Company Calendar Last Earnings8/12/2025Today8/24/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MIST CIK1408443 Webwww.milestonepharma.com Phone(514) 336-0444FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Milestone Pharmaceuticals$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+194.1%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.52 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,672.29% Return on Assets-83.09% Debt Debt-to-Equity Ratio4.06 Current Ratio4.97 Quick Ratio4.97 Sales & Book Value Annual Sales$1 million Price / Sales144.48 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / Book-8.10Miscellaneous Outstanding Shares84,990,000Free Float68,420,000Market Cap$144.48 million OptionableOptionable Beta0.52 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:MIST) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.